{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:56:34Z","timestamp":1790034994813,"version":"4.0.1"},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.18632\/oncotarget.11644","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T22:07:14Z","timestamp":1472681234000},"page":"72343-72355","source":"Crossref","is-referenced-by-count":64,"title":["Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses"],"prefix":"10.18632","volume":"7","author":[{"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[{"name":"Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Ciani","sequence":"additional","affiliation":[{"name":"Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy"},{"name":"Evidence Synthesis and Modelling for Health Improvement (ESMI), University of Exeter Medical School, South Cloisters, St Luke's Campus, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sommariva","sequence":"additional","affiliation":[{"name":"Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Facciorusso","sequence":"additional","affiliation":[{"name":"Department of Surgery, Liver Surgery, Transplantation and Gastroenterology, Istituto Nazionale Tumori Fondazione IRCCS, National Cancer Institute of Milan, and University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Tarricone","sequence":"additional","affiliation":[{"name":"Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy"},{"name":"Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bhoori","sequence":"additional","affiliation":[{"name":"Department of Surgery, Liver Surgery, Transplantation and Gastroenterology, Istituto Nazionale Tumori Fondazione IRCCS, National Cancer Institute of Milan, and University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"Department of Surgery, Liver Surgery, Transplantation and Gastroenterology, Istituto Nazionale Tumori Fondazione IRCCS, National Cancer Institute of Milan, and University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"2","unstructured":"IARC Globocan. 2012. http:\/\/globocaniarcfr\/Pages\/fact_sheets_canceraspx. Last accessed online in June 2016 from."},{"key":"3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Bruix","year":"2012","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J Hepatol"},{"key":"5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Williams","year":"1973","journal-title":"Br J Surg"},{"key":"6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Sherman","year":"2011","journal-title":"Hepatology"},{"issue":"Supplement 1","key":"7","first-page":"S12","article-title":"Hepatocellular Carcinoma (HCC): An Update","volume":"34","author":"Taiebc","year":"2007","journal-title":"Sem Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Zeuzem","year":"2008","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Liang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Colombo","year":"2011","journal-title":"Hepatology"},{"key":"11","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26382","article-title":"Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives","volume":"58","author":"Sangro","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl 7","key":"12","first-page":"vii41","article-title":"Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Rougier","year":"2012","journal-title":"Ann Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","article-title":"Radioembolization for hepatocellular carcinoma","volume":"56","author":"Bilbao","year":"2012","journal-title":"J Hepatol"},{"key":"14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","article-title":"Prospective Randomized Pilot Study of Y90 +\/\u2212 Sorafenib as Bridge to Transplantation in Hepatocellular Carcinoma","volume":"61","author":"Baker","year":"2014","journal-title":"Journal of Hepatology"},{"key":"15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Tatsch","year":"2015","journal-title":"Liver Int"},{"key":"16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/liv.12574","article-title":"Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis","volume":"35","author":"Trevisani","year":"2015","journal-title":"Liver Int"},{"key":"17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/000313480407001103","article-title":"Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma","volume":"70","author":"Imagawa","year":"2004","journal-title":"Am Surg"},{"key":"18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/153303460900800109","article-title":"Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities","volume":"8","author":"Rich","year":"2009","journal-title":"Technol Cancer Res Treat"},{"key":"19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jamcollsurg.2008.12.009","article-title":"Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?","volume":"208","author":"Martin","year":"2009","journal-title":"J Am Coll Surg"},{"key":"20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study","volume":"116","author":"Branch","year":"2010","journal-title":"Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Antoch","year":"2010","journal-title":"Hepatology"},{"key":"22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jvir.2009.10.013","article-title":"Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma","volume":"21","author":"Kim","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Gupta","year":"2010","journal-title":"Gastroenterology"},{"key":"24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jvir.2010.04.027","article-title":"Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis","volume":"21","author":"O'Neil","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-011-1881-2","article-title":"Intra-arterial treatment with Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital","volume":"38","author":"Defreyne","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","article-title":"Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma","volume":"22","author":"Menon","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"Giampalma","year":"2011","journal-title":"Hepatology"},{"key":"28","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"Camerini","year":"2013","journal-title":"Hepatology"},{"key":"29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","article-title":"Efficacy and safety of transarterial radioembolizationchemoembolization in patients with hepatocellular carcinoma","volume":"36","author":"Gores","year":"2013","journal-title":"Cardiovasc. Intervent. Radiol"},{"key":"30","doi-asserted-by":"crossref","first-page":"e82225","DOI":"10.1371\/journal.pone.0082225","article-title":"A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization","volume":"8","author":"Schlaak","year":"2013","journal-title":"PLoS One"},{"key":"31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12072-014-9533-9","article-title":"Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma","volume":"8","author":"Irani","year":"2014","journal-title":"Hepatol Int"},{"key":"32","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/jgh.12621","article-title":"Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres","volume":"29","author":"Law","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jvir.2014.03.030","article-title":"Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity","volume":"25","author":"Harris","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.ijsu.2014.07.269","article-title":"Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients","volume":"12","author":"Bester","year":"2014","journal-title":"Int J Surg"},{"key":"35","first-page":"185","article-title":"Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection","volume":"3","author":"Lo","year":"2014","journal-title":"Hepatobiliary Surg Nutr"},{"key":"36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.12637","article-title":"In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?","volume":"35","author":"Schlaak","year":"2015","journal-title":"Liver Int"},{"key":"37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.114.145177","article-title":"Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis","volume":"56","author":"Clement","year":"2015","journal-title":"J Nucl Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/cbr.2014.1748","article-title":"Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis","volume":"30","author":"Turkmen","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12149-015-0962-x","article-title":"Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy","volume":"29","author":"Kir","year":"2015","journal-title":"Ann Nucl Med"},{"key":"40","first-page":"503","article-title":"A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres","volume":"56","author":"Camerini","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/COC.0b013e3181df0a50","article-title":"Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations","volume":"34","author":"Wasan","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1017\/S0266462314000300","article-title":"Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers","volume":"30","author":"Taylor","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"43","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Abo-Zaid","year":"2010","journal-title":"BMJ"},{"key":"44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jgh.13147","article-title":"Drug-eluting beadsconventional chemoembolization for the treatment of unresectable hepatocellular carcinoma","volume":"31","author":"Mazzaferro","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Trevisani","year":"2014","journal-title":"Br J Cancer"},{"key":"46","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jvir.2014.04.014","article-title":"Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma","volume":"25","author":"Cressman","year":"2014","journal-title":"J Vasc Interv Radiol"},{"key":"47","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Altman","year":"2010","journal-title":"Int J Surg"},{"key":"48","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Statistics in Medicine"},{"key":"49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"50","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia. A case study for technology appraisal on the basis of surrogate outcomes evidence","volume":"16","author":"Taylor","year":"2013","journal-title":"Value Health"},{"key":"51","unstructured":"CRD, Systematic Reviews: CRD's guidance for undertaking reviews in health care. 2009. York, University of York CRD."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:23:11Z","timestamp":1718770991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":51,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["11644","27579537"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11644","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]}}}